PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

• M. Hultcrantz,
• D. Kleinman,
• P. Ghataorhe,
• A. Mckeown,
• W. He,
• T. Ling,
• R. C. Jewell,
• J. Byrne,
• L. Eliason,
• E. Scott,
• J. Opalinska

Affiliations

M. Hultcrantz

1 Memorial Sloan Kettering Cancer Center, New York

D. Kleinman

2 University of Rochester, Rochester, NY, United States of America

P. Ghataorhe

3 GlaxoSmithKline, London, United Kingdom

A. Mckeown

3 GlaxoSmithKline, London, United Kingdom

W. He

4 GlaxoSmithKline, Cambridge, MA

T. Ling

3 GlaxoSmithKline, London, United Kingdom

R. C. Jewell

5 GlaxoSmithKline, Research Triangle Park, NC

J. Byrne

6 GlaxoSmithKline, Upper Providence, PA, United States of America

L. Eliason

6 GlaxoSmithKline, Upper Providence, PA, United States of America

E. Scott

6 GlaxoSmithKline, Upper Providence, PA, United States of America

J. Opalinska

6 GlaxoSmithKline, Upper Providence, PA, United States of America